Next Article in Journal
Mineral Bioaccessibility and Antioxidant Capacity of Protein Hydrolysates from Salmon (Salmo salar) and Mackerel (Scomber scombrus) Backbones and Heads
Next Article in Special Issue
Anthraquinone Derivatives and Other Aromatic Compounds from Marine Fungus Asteromyces cruciatus KMM 4696 and Their Effects against Staphylococcus aureus
Previous Article in Journal
Microalgae from Cold Environments and Their Possible Biotechnological Applications
Previous Article in Special Issue
Thiolactones and Δ8,9-Pregnene Steroids from the Marine-Derived Fungus Meira sp. 1210CH-42 and Their α-Glucosidase Inhibitory Activity
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Diketopiperazine Alkaloids and Bisabolene Sesquiterpenoids from Aspergillus versicolor AS-212, an Endozoic Fungus Associated with Deep-Sea Coral of Magellan Seamounts

1
CAS and Shandong Province Key Laboratory of Experimental Marine Biology, Institute of Oceanology, Chinese Academy of Sciences, Nanhai Road 7, Qingdao 266071, China
2
Laboratory of Marine Biology and Biotechnology, Qingdao National Laboratory for Marine Science and Technology, Wenhai Road 1, Qingdao 266237, China
3
University of Chinese Academy of Sciences, Yuquan Road 19A, Beijing 100049, China
4
Center for Ocean Mega-Science, Chinese Academy of Sciences, Nanhai Road 7, Qingdao 266071, China
*
Authors to whom correspondence should be addressed.
Mar. Drugs 2023, 21(5), 293; https://doi.org/10.3390/md21050293
Submission received: 4 April 2023 / Revised: 4 May 2023 / Accepted: 8 May 2023 / Published: 10 May 2023
(This article belongs to the Special Issue Bioactive Secondary Metabolites of Marine Fungi)

Abstract

:
Two new quinazolinone diketopiperazine alkaloids, including versicomide E (2) and cottoquinazoline H (4), together with ten known compounds (1, 3, and 512) were isolated and identified from Aspergillus versicolor AS-212, an endozoic fungus associated with the deep-sea coral Hemicorallium cf. imperiale, which was collected from the Magellan Seamounts. Their chemical structures were determined by an extensive interpretation of the spectroscopic and X-ray crystallographic data as well as specific rotation calculation, ECD calculation, and comparison of their ECD spectra. The absolute configurations of (−)-isoversicomide A (1) and cottoquinazoline A (3) were not assigned in the literature reports and were solved in the present work by single-crystal X-ray diffraction analysis. In the antibacterial assays, compound 3 exhibited antibacterial activity against aquatic pathogenic bacteria Aeromonas hydrophilia with an MIC value of 18.6 μM, while compounds 4 and 8 exhibited inhibitory effects against Vibrio harveyi and V. parahaemolyticus with MIC values ranging from 9.0 to 18.1 μM.

1. Introduction

Marine-derived fungi living under extreme survival conditions are considered as abundant sources of structurally diverse and biologically active compounds [1,2]. In the deep-sea habitats, seamounts are regarded locations for a wide variety of current-topography interactions and biophysical coupling which have large biomass and higher biodiversity than their surrounding deep-sea floors [3,4]. Endozoic fungi surviving in deep-sea seamounts are a promising new source to mining bioactive secondary metabolites owing to their unique habitats. To date, only three papers investigating bioactive secondary metabolites of fungi derived from deep-sea seamounts have been published [5,6,7]. Therefore, a study on the chemical diversity of deep-sea seamount-derived endozoic fungi is warranted.
The species in the fungal genus Aspergillus, especially A. versicolor, is widely distributed in various habitats (marine, terrestrial, and symbiotic sources) and possesses the ability to produce diversified bioactive secondary metabolites such as diketopiperazine alkaloids [8,9], peptides [10], xanthones [9,11], and sesquiterpenes [12]. Most of these metabolites are described to exhibit a variety of bioactivities, including antifungal [9], antitumor [10,11], and neuroprotective activities [12].
In our continuous efforts to explore bioactive metabolites from deep-sea seamount-derived fungi [5,6,7], chemical investigation of the endozoic fungus Aspergillus versicolor AS-212 associated with the deep-sea coral, Hemicorallium cf. imperiale, which was collected from the Magellan Seamounts in the Western Pacific Ocean was carried out due to its unique HPLC profiles. As a result, two new quinazolinone diketopiperazine alkaloids, namely, versicomide E (2) and cottoquinazoline H (4), together with five known related analogs (1, 3, 57) as well as four known bisabolene derivatives (811) and a bisabolene dimer (12), have been isolated and identified. Herein, we report the isolation and structure elucidation as well as the antimicrobial activities of compounds 112 (Figure 1).

2. Results and Discussion

2.1. Structure Elucidation of the Isolated Compounds

Compound 1 was isolated as colorless crystals, and the molecular formula was established as C19H25N3O3 by analysis of the HRESIMS data. The 1H and 13C NMR of 1 (DMSO-d6, Table 1) extremely resembled those of versicomide A, a quinazoline-containing compound isolated from the crab-derived fungus Aspergillus versicolor XZ-4 which was collected from hydrothermal vent [8]. Further analysis of the 2D NMR spectra (Figure 2) indicated the same planar structure of 1 as that of versicomide A (Figure 1). However, a strong NOE cross-peak of H-3/H-20 was in favor of the structure with the 3S*- and 14R*-relative configuration rather than a 3S* and 14S* configuration (Figure 3). Single-crystal X-ray diffraction analysis with Cu Kα radiation further demonstrated its structure and absolute configurations (Figure 4). A Flack parameter of 0.0(2) enabled the definition of its absolute configuration as 3S, 14R, and 15S, indicating that 1 was the 14-epimer of versicomide A.
Compound 1 was initially treated as a new quinazoline alkaloid during the preparation of this manuscript, while Tasdemir and co-workers recently reported a new quinazoline-containing diketopiperazine (−)-isoversicomide A from the deep-sea sediment-derived fungus Aspergillus versicolor PS108-62 [13]. Notably, compound 1 shared the same planar structure and virtually similar optical rotation value ( [ α ] D 25 −30 vs. [ α ] D 20 −25) as that of (−)-isoversicomide A, in which the stereogenic centers at C-3 and C-14 showed the same relative configurations with that of compound 1. However, the configuration at C-18 on the short flexible aliphatic chain and the absolute configuration of (−)-isoversicomide A were not assigned due to the limited sample available [13]. Considering their similar rotation values and same relative configuration at C-3 and C-14, we assumed that compound 1 and (−)-isoversicomide A are the same compound. As the reported evidence to determine the absolute configuration of versicomide A does not seem entirely solid and in view of the highly similar NMR data of those isomers with multi-chiral centers, it is necessary to clarify the absolute configuration of 1. The results from the X-ray diffraction analysis of compound 1 unambiguously determined its absolute configuration as 3S, 14R, and 15S. This is likely the first time the configuration of isoleucine in a quinazoline-containing diketopiperazine skeleton with a Val-Ile cyclic dipeptide moiety was unambiguously defined by X-ray crystallography analysis.
Versicomide E (2) was obtained as a colorless amorphous solid with the molecular formula C19H23N3O3 based on the HRESIMS data. Its NMR data (CDCl3, Table 1) were similar to those of 1, which indicated that 2 possessed the same quinazoline backbone as 1. The obvious difference was the absence of signals for two methines at δC 58.1/δH 4.70 (CH-3) and δC 36.1/δH 2.62 (CH-15) in the NMR spectra of 1, whereas additional resonances corresponding to a tetra-substituted double bond at δC 121.3 (C-3) and δC 135.0 (C-15) were found in that of 2 (CDCl3, Table 1), which were further confirmed by COSY and HMBC correlations (Figure 2). The geometry of the double bond between C-3 and C-15 was determined as Z-configuration by key NOE correlations from NH-2 (δH 8.02) to H-16 (δH 2.29) and H3-17 (δH 1.15) (Figure 3). Compound 2 has the same planar structure as that of versicomide B (Figure 1), which was also isolated from hydrothermal vent crab-derived fungus Aspergillus versicolor XZ-4 by Wu and co-workers in 2017 [8], with the exception of the geometry of the double bond at C3(15) (Z in 2 vs. E in versicomide B) and the absolute configuration of C-14 (R in 2 vs. S in versicomide B) as well. To clarify the stereochemistry of compound 2, calculations of specific rotation (SR) were carried out for 14R-2 and 14S-2, and the calculated SR value for 14R-2 (+59.8) at CAM-B3LYP/TZVP level was compatible with the experimental SR value [ α ] D 25 +112.0 (c 0.08, MeOH), contrary to that of versicomide B ( [ α ] D 20 −23.4) [8], which allowed the assignment of absolute configuration of C-14 in 2 as 14R (Table S2). To further verify the absolute configuration of C-14 in 2, the time-dependent density functional (TDDFT)-ECD calculation was performed on 14R-2 and 14S-2 at the CAM-B3LYP/TZVP level in Gaussian 09. The experimental curve matched that of the calculated ECD spectrum for 14R-2 and also assigned the absolute configuration of C-14 in 2 as 14R (Figure S27).
Compound 3 was obtained as colorless prisms and was identified as cottoquinazoline A by comparing its NMR data (measured in DMSO-d6, Table S3) with those previously reported in the literature [10]. Cottoquinazoline A is a 16-nor analog of the known fumiquinazoline D and was first isolated from a marine-derived fungal strain of A. versicolor (MST-MF495) by Capon and co-workers in 2009, with a partial stereostructure assigned [10]. Considering the complexity of the structure of 3 and the presence of many stereoisomers, it is important to clarify the assignment of the absolute configurations of 3 [10,14]. Fortunately, a suitable crystal of 3 was picked out from DMSO–MeOH (1:1) and subjected to X-ray crystallographic analysis to assign its absolute configurations of the stereogenic centers in 3 as 3S, 14S, 16R, 17S, and 19S (Figure 4).
Cottoquinazoline H (4) was obtained as a colorless amorphous solid. Its molecular formula was established as C24H21N5O4 by HRESIMS, with one CH2 unit more than that of 3. Discreet comparisons of the NMR data (DMSO-d6, Table 2) and UV absorptions with 3 suggested that they shared the same core scaffold. However, the methyl substitution at C-20 in 3 was replaced by an ethyl group in 4, as evidenced by the appearance of an additional methylene group resonating at δC 21.0 and δH 1.90/1.99 (CH2-29) in the NMR spectra of 4 (DMSO-d6, Table 2). Additionally, the chemical shift of C-20 was deshielded downfield from δC 63.2 in 3 to δC 68.1 in 4. The COSY and HMBC correlations verified the above deduction (Figure 2). The relative configuration of 4 was also deduced from the analysis of NOESY experiments. The NOE cross-peaks from H-20 and H-15α to H-18 revealed the cofacial orientation of these groups (Figure 3). Given that the stereochemistry of co-isolated compound 3 was determined by X-ray diffraction analysis as well as their similar NMR chemical shifts and virtually identical experimental ECD curves (Figure 5), the absolute configurations of all chiral carbons in 4 were established as 3S, 14S, 17R, 18S, and 20S.
In addition to compounds 14, three related quinazolinone diketopiperazine alkaloids, namely, versicoloids A and B (5 and 6) [9], and chrysopiperazine A (7) [15], as well as five known bisabolene derivatives (812) including sydonic acid (8) [16], (S)-(+)-11-dehydrosydonic acid (9) [17], (−)-10-hydroxysydonic acid (10) [18], hydroxysydonic acid (11) [16], and peniciaculin B (12) [18] were also identified and isolated from the fungus A. versicolor AS-212, which were determined by the comparison of their NMR data and those previously described in the literature. Structurally, (−)-isoversicomide A (1) might be a plausible biosynthetic precursor that undergoes the transformation of the benzene ring to the oxepine ring to generate versicoloid A (5) [19], which provides the basis for the biosynthetic origins of versicoloid A.

2.2. Antimicrobial Assays

The antimicrobial activity evaluation of all the isolated compounds was performed against human pathogenic bacterium (Escherichia coli), marine-derived aquatic pathogenetic bacteria (Aeromonas hydrophila, Edwardsiella ictarda, Micrococcus luteus, Pseudomonas aeruginosa, Vibrio harveyi, V. parahemolyticus, V. vulnificus), and plant-pathogenic fungi (Colletotrichum gloeosporioides, Curvularia spicifera, Epicoccum sorghinum, Fusarium oxysporum, F. proliferatum, and Penicillium digitatum) (Table 3). In the antimicrobial screening, compounds 4 and 8 exhibited potent inhibitory activity against the aquatic pathogenic bacterium V. parahaemolyticus with MIC values of 9.0 and 15.0 μM, while compounds 8 and 9 showed inhibitory activity against the aquatic pathogenic bacterium V. harveyi with the MIC values of 15.0 and 15.2 μM. In addition, compounds 3 and 4 displayed a broad spectrum of antimicrobial activity against most of the tested strains, with the MIC values ranging from 9.0 to 74.6 μM. The bisabolene derivatives (812) mainly exhibited activities against M. luteus, V. harveyi, and V. parahaemolyticus, with MIC values ranging from 15.0 to 121.2 μM. However, neither the quinazoline-containing diketopiperazine derivatives (1 and 2) nor the oxepine-containing diketopiperazine analogs (57) showed any activity against all the tested pathogenic bacteria. These data suggested that the 16-nor-methyl fumiquinazoline alkaloids generally showed higher antimicrobial activity than that of quinazolinone alkaloids (3 and 4 vs. 1 and 2) and the oxepine congeners (57). A comparison of the antimicrobial results of 3 and 4 revealed that different substituent groups at C-20 could influence the inhibitory potency against the pathogenic bacteria. Concerning bisabolene derivatives, the antimicrobial results revealed that compound 12, a dimeric bisabolene analog, showed weaker antimicrobial activities than that of the monomeric bisabolenes (811) against M. luteus and V. harveyi. In addition, hydroxylation at C-10 or C-11 likely decreased the activity against V. harveyi, V. parahaemolyticus, and C. gloeosporioides (8 vs. 10 and 11).
The above results showed that compounds 4, 8, and 9 were found to be efficient in suppressing the growth of aquatic pathogenic bacteria V. parahaemolyticus and V. harveyi. To a great degree, the endozoic fungus A. versicolor AS-212 which is associated with the deep-sea coral Hemicorallium cf. imperiale may provide a chemical defense to help its host to fight off the aquatic pathogenic bacteria by producing an array of antimicrobial secondary metabolites.

3. Experimental Section

3.1. General Experimental Procedures

The general experimental procedures, apparatus, and solvents/reagents used in this work were the same as those described in our previous reports [5,6,7].

3.2. Fungal Material

The endophytic fungus Aspergillus versicolor AS-212 associated with deep-sea coral, Hemicorallium cf. imperial, was collected from the Magellan Seamounts (depth 1420 m) in May 2018. By comparing its ITS region sequence with that of A. versicolor (accession no. MT582751.1) in the GenBank database, the sequence data of strain AS-212 were identical (100%) to those of A. versicolor and subsequently uploaded in GenBank with accession no. OP009765.1. The fungus AS-212 has been conserved at the Key Laboratory of Experimental Marine Biology, Institute of Oceanology, Chinese Academy of Sciences (IOCAS).

3.3. Fermentation, Extraction, and Isolation

The fungal strain AS-212 was cultivated on potato dextrose agar (PDA) plates at 28 °C for 7 days to generate spores. The fresh mycelia were transferred into 1 L Erlenmeyer flasks, each containing 300 mL potato-dextrose broth (PDB) medium, which was reported in our previous publication [5], and fermented under static conditions for 30 days at room temperature. After 30 days of incubation, a total of 33 L cultures were filtered and collected to separate the broth and mycelia. The broth was adequately extracted three times with EtOAc, while the mycelia were mechanically crushed and then extracted three times with 80% volume aqueous acetone. Acetone was removed in vacuo to afford an aqueous solution, which was successively extracted with EtOAc. Based on their virtually similar TLC and HPLC profiles (Figure S26), both EtOAc extracts from broth and mycelia were combined and evaporated under a vacuum to render the EtOAc extract (61 g).
The EtOAc extract was subjected to vacuum liquid chromatography (VLC) eluted with petroleum ether (PE)–EtOAc gradient (20:1 to 1:1, v/v) and then CH2Cl2–MeOH (20:1 to 1:1, v/v) to afford nine fractions (Frs. 1–9). Fr. 4 (2.3 g) was fractionated by reverse-phase column chromatography (CC) with a MeOH–H2O gradient (from 10:90 to 100:0) to afford nine subfractions (Frs.4.1–4.9). Fr. 4.2 was directly purified by semi-preparative HPLC (Elite ODS-BP, 5µm; 10 × 250 mm; 80% MeOH–H2O, 2.5 mL/min) to yield compound 6 (3.0 mg, tR = 17 min). Fr. 4.4 (16 mg) was further purified by prep. TLC (plate: 20 × 20 cm, developing solvents: PE–EtOAc, 2:1) and by Sephadex LH-20 (MeOH) column to afford 7 (3.1 mg). Fr. 4.5 was purified by CC over Sephadex LH-20 chromatography (MeOH) and then by semi-preparative HPLC (85% MeOH–H2O, 2.5 mL/min) to give compound 1 (6.6 mg, tR = 14 min). Fr. 4.6 (75 mg) was fractionated by CC on Sephadex LH-20 column (MeOH) to yield five subfractions Frs.4.6.1–4.6.5. Fr. 4.6.5 (20 mg) was further purified by prep. TLC (developing solvents: DCM–MeOH, 20:1) and by Sephadex LH-20 (MeOH) to afford compound 9 (7.7 mg). Fr. 4.7 (36 mg) was directly purified by prep. TLC (developing solvents: CH2Cl2–EtOAc, 3:1) and by Sephadex LH-20 (MeOH) to afford compound 8 (4.0 mg). Fr. 4.8 (67 mg) was purified by CC on silica gel eluting with CH2Cl2–MeOH gradient (from 200:1 to 50:1) to obtain compound 12 (4.3 mg). Fr. 5 (3.4 g) was separated by reversed-phase CC using step-gradient elution with MeOH–H2O (from 10:90 to 100:0) to yield seven subfractions (Frs. 5.1–5.7). Fr. 5.2 (241 mg) was fractionated by CC on silica gel eluting with CH2Cl2–MeOH gradient (from 150:1 to 20:1) and then purified on Sephadex LH-20 (MeOH) to afford compounds 10 (11.3 mg) and 11 (4.3 mg). Fr. 5.4 (126 mg) was fractionated by CC on Sephadex LH-20 (MeOH) and further purified by semi-preparative HPLC (70% MeOH–H2O, 2.5 mL/min) to afford compound 5 (6.3 mg, tR = 22 min). Fr. 5.6 was chromatographed via a Sephadex LH-20 column (MeOH) and then by semi-preparative HPLC (78% MeOH-H2O, 2.5 mL/min) to afford compound 2 (6.7 mg, tR = 20 min). Fr. 7 (5.8 g) was fractionated by reverse-phase CC with a MeOH–H2O gradient (from 10:90 to 100:0) to yield five subfractions (Frs. 7.1–7.5). Fr. 7.5 (328 mg) was applied to silica gel CC eluted with CH2Cl2/MeOH to give nine subfractions (Frs. 7.5.1–7.5.9). Fr.7.5.7 (36 mg) was purified by semi-preparative HPLC (45% MeCN–H2O, 2.5 mL/min) to provide compounds 3 (4.3 mg, tR = 9 min) and 4 (3.2 mg, tR = 12 min).
 
(−)-Isoversicomide A (1): colorless crystals; mp 197−199 °C; [ α ] D 25 −30 (c 0.10, MeOH); UV (MeOH) λmax (log ε) 227 (3.47), 277 (3.00), 326 (2.58) nm; ECD (0.52 mM, MeOH) λmaxε) 210 (−4.87), 233 (−15.03), 277 (+1.88), 328 (−1.02) nm; for 1H and 13C NMR data, see Table 1; HRESIMS m/z 344.1960 [M + H]+ (calcd for C19H26N3O3, 344.1969).
 
Versicomide E (2): colorless amorphous solid; [ α ] D 25 +112 (c 0.08, MeOH); UV (MeOH) λmax (log ε) 221 (3.26), 309 (2.88) nm; ECD (0.59 mM, MeOH) λmaxε) 207 (+6.69), 233 (−3.87), 255 (+6.18), 300 (+1.41), 343 (−1.15) nm; for 1H and 13C NMR data, see Table 1; HRESIMS m/z 340.1663 [M − H] (calcd for C19H22N3O3, 340.1667).
 
Cottoquinazoline A (3): colorless prisms (MeOH-DMSO 1:1); mp 215−217 °C; [ α ] D 25 +160 (c 0.10, MeOH); UV (MeOH) λmax (log ε) 205 (3.39), 227 (3.17), 256 (2.81), 268 (2.74), 280 (2.68), 305 (2.26), 315 (2.14) nm; ECD (0.58 mM, MeOH) λmaxε) 211 (−13.16), 230 (+12.22), 308 (+3.60) nm; for 1H and 13C NMR data, see Table S2.
 
Cottoquinazoline H (4): colorless amorphous solid; [ α ] D 25 +150 (c 0.10, MeOH); UV (MeOH) λmax (log ε) 205 (3.60), 227 (3.43), 257 (3.11), 270 (3.03), 279 (2.96), 304 (2.52), 317 (2.40) nm; ECD (0.56 mM, MeOH) λmaxε) 212 (−22.91), 231 (+21.65), 308 (+7.16) nm; for 1H and 13C NMR data, see Table 2; HRESIMS m/z 444.1663 [M + H]+ (calcd for C24H22N5O4, 444.1666).

3.4. X-ray Crystallographic Analysis of Compounds 1 and 3

Suitable crystals were picked out to obtain crystallographic data using a Bruker Smart-1000 or Bruker D8 VENTURE CCD diffractometer with Cu Kα radiation (λ = 1.54178 Å). Absorption correction was applied using the program SADABS [20]. The structures were solved by direct methods with the SHELXTL software package [21,22]. All non-hydrogen atoms were refined anisotropically. The absolute structures were determined by refinement of the Flack parameter [23]. The structures were optimized by full-matrix least-squares techniques. Crystallographic data have been deposited with the Cambridge Crystallographic Data Centre with deposition numbers CCDCs 2192654 and 2192653 for 1 and 3, respectively. Crystal data and structure refinements for 1 and 3 are listed in Table S1.
Crystal data for compound 1: C19H25N3O3, F.W. = 343.2, space group P2(1)2(1)2(1), unit cell dimensions a = 13.2384(3) Å, b = 19.9347(4) Å, c = 6.8103(2) Å, V = 1797.26(8) Å3, α = β = γ = 90°, Z = 4, dcalcd = 1.269 g/cm3, crystal dimensions 0.350 × 0.330 × 0.300 mm, μ = 0.702 mm–1, F(000) = 736. The 4007 measurements yielded 2826 independent reflections after equivalent data were averaged. The final refinement gave R1 = 0.0379 and wR2 = 0.0989 [I > 2σ(I)]. Flack parameter = 0.0(2).
Crystal data for compound 3: 2(C23H18N5O4)·C2OS2, F.W. = 960.99, orthorhombic space group C2221, unit cell dimensions a = 9.4022(11) Å, b = 25.878(4) Å, c = 19.112(2) Å, V = 4650.2(11) Å3, α = β = γ = 90°, Z = 4, dcalcd = 1.373 g/cm3, crystal dimensions 0.200 × 0.180 × 0.150 mm, μ = 1.612 mm–1, F(000) = 1992. The 21,138 measurements yielded 4267 independent reflections after equivalent data were averaged. The final refinement gave R1 = 0.0951 and wR2 = 0.2851 [I > 2σ(I)]. Flack parameter = 0.145(12).

3.5. Antimicrobial Assay

A two-fold serial dilution method using 96-well microtiter plates was applied to evaluating the antimicrobial activities against a panel of aquatic pathogenic bacteria (Aeromonas hydrophilia QDIO-1, Edwardsiella ictarda QDIO-9, Micrococcus luteus QDIO-3, Pseudomonas aeruginosa QDIO-4, Vibrio harveyi QDIO-7, V. parahaemolyticus QDIO-8, and V. vulnificus QDIO-10), one human pathogenic bacterium (Escherichia coli EMBLC-1), and six plant-pathogenic fungi (Penicillium digitatum QDAU-3, Colletotrichum gloeosporioides QA-29, Fusarium oxysporum QDAU-8, Curvularia spicifera QA-26, Epicoccum sorghinum QA-20, and F. proliferatum QA-28) [24]. The aquatic pathogenic strains and human pathogenic bacterium were provided by IOCAS, while the plant-pathogenic fungi were provided by IOCAS and Qingdao Agricultural University. To assay the antimicrobial activities, DMSO was added to dissolve all isolated compounds and positive control (chloramphenicol and amphotericin B) to prepare a stock solution with a specific concentration.

3.6. Specific Rotation and ECD Calculations

General computational procedures were consistent with our previous reports [5,25].

4. Conclusions

In conclusion, two new quinazolinone derivatives, versicomide E (2) and cottoquinazoline H (4), along with ten known compounds (1, 3, and 512), were isolated and identified from the deep-sea coral-derived Aspergillus versicolor AS-212. This marks the first time that the absolute configurations of all the stereogenic centers in (−)-isoversicomide A (1) and cottoquinazoline A (3), which were not assigned in the previous literature, were accurately solved in the present work by X-ray crystallographic analysis. Compound 3 exhibited activity against aquatic pathogenic bacteria A. hydrophilia with an MIC value of 18.6 μM, while compounds 4 and 810 exhibited inhibitory effects against V. harveyi with MIC values ranging from 15.0 to 28.4 μM. In addition, compounds 4 and 8 exhibited potent inhibitory effects against V. parahaemolyticus with MIC values of 9.0 and 15.0 μM, which might have the potential to be developed as leading compounds in discovering aquatic antibiotics.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/md21050293/s1, Figures S1–S27: The analyzed data of MS, 1D and 2D NMR spectra of compounds 14, crystal packing of compounds 1 and 3, HPLC analysis of mycelia extract, broth extract, and compounds 112 of Aspergillus versicolor AS-212, and experimental and calculated ECD spectra of compound 2 at the CAM-B3LYP/TZVP level. Table S1: Crystal data and structure refinement for compounds 1 and 3. Table S2: Calculated specific rotation values at 589.44 nm for the enantiomers 14R-2 and 14S-2 at the CAM-B3LYP/TZVP level. Table S3: 1H and 13C NMR spectroscopic data for compound 3.

Author Contributions

Y.-L.D. performed the experiments for the extraction, isolation, structure elucidation, and bioactivity evaluation and prepared the manuscript; X.-M.L. performed the 1D and 2D NMR experiments; X.-S.S. and Y.-R.W. contributed to the isolation, identification, and small-scale screening of the fungus AS-212. L.-H.M. contributed to NMR analysis and structure elucidation; B.-G.W. supervised the research work and revised the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

This work was financially supported by the National Natural Science Foundation of China (U2006203 and 41976090), the Senior User Project of RV KEXUE (KEXUE2020GZ02), and the Shandong Provincial Natural Science Foundation (ZR2021ZD28 and ZR2019ZD18).

Data Availability Statement

Not applicable.

Acknowledgments

B.-G.W. acknowledges the support of the Research Vessel KEXUE of the National Major Science and Technology Infrastructure from the Chinese Academy of Sciences (for sampling).

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Newman, D.J.; Cragg, G.M. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. J. Nat. Prod. 2020, 83, 770–803. [Google Scholar] [CrossRef]
  2. Wang, Y.N.; Meng, L.H.; Wang, B.G. Progress in research on bioactive secondary metabolites from deep-sea derived microorganisms. Mar. Drugs 2020, 18, 614. [Google Scholar] [CrossRef]
  3. Xu, K.D. Exploring seamount ecosystems and biodiversity in the tropical Western Pacific Ocean. J. Oceanol. Limnol. 2021, 39, 1585–1590. [Google Scholar] [CrossRef]
  4. Clark, M.R.; Rowden, A.A.; Schlacher, T.; Williams, A.; Consalvey, M.; Stocks, K.I.; Rogers, A.D.; O’Hara, T.D.; White, M.; Shank, T.M. The ecology of seamounts: Structure, function, and human impacts. Annu. Rev. Mar. Sci. 2010, 2, 253–278. [Google Scholar] [CrossRef] [PubMed]
  5. Meng, L.H.; Li, X.M.; Zhang, F.Z.; Wang, Y.N.; Wang, B.G. Talascortenes A–G, highly oxygenated diterpenoid acids from the sea-anemone-derived endozoic fungus Talaromyces scorteus AS-242. J. Nat. Prod. 2020, 83, 2528–2536. [Google Scholar] [CrossRef] [PubMed]
  6. Hu, X.Y.; Li, X.M.; Wang, B.G.; Meng, L.H. Tanzawaic acid derivatives: Fungal polyketides from the deep-sea coral-derived endozoic Penicillium steckii AS-324. J. Nat. Prod. 2022, 85, 1398–1406. [Google Scholar] [CrossRef]
  7. Hu, X.Y.; Li, X.M.; Wang, B.G.; Meng, L.H. Uncommon polyketides from Penicillium steckii AS-324, a marine endozoic fungus isolated from deep-sea coral in the Magellan seamount. Int. J. Mol. Sci. 2022, 23, 6332. [Google Scholar] [CrossRef]
  8. Pan, C.Q.; Shi, Y.T.; Chen, X.G.; Chen, C.A.; Tao, X.Y.; Wu, B. New compounds from a hydrothermal vent crab-associated fungus Aspergillus versicolor XZ-4. Org. Biomol. Chem. 2017, 15, 1155–1163. [Google Scholar] [CrossRef]
  9. Wang, J.F.; He, W.J.; Huang, X.L.; Tian, X.P.; Liao, S.R.; Yang, B.; Wang, F.Z.; Zhou, X.J.; Liu, Y.H. Antifungal new oxepine-containing alkaloids and xanthones from the deep-sea-derived fungus Aspergillus versicolor SCSIO 05879. J. Agric. Food Chem. 2016, 64, 2910–2916. [Google Scholar] [CrossRef]
  10. Fremlin, L.J.; Piggott, A.M.; Lacey, E.; Capon, R.J. Cottoquinazoline A and cotteslosins A and B, metabolites from an Australian marine-derived strain of Aspergillus versicolor. J. Nat. Prod. 2009, 72, 666–670. [Google Scholar] [CrossRef]
  11. Yu, G.H.; Wu, G.W.; Sun, Z.C.; Zhang, X.M.; Che, Q.; Gu, Q.Q.; Zhu, T.J.; Li, D.H.; Zhang, G.J. Cytotoxic tetrahydroxanthone dimers from the mangrove-associated fungus Aspergillus versicolor HDN1009. Mar. Drugs 2018, 16, 335. [Google Scholar] [CrossRef] [PubMed]
  12. Weng, H.Z.; Zhu, J.Y.; Yuan, F.Y.; Tang, Z.Y.; Tian, X.Q.; Chen, Y.; Fan, C.Q.; Tang, G.H.; Yin, S. Homo/Hetero-dimers of aromatic bisabolane sesquiterpenoids with neuroprotective activity from the fungus Aspergillus versicolor A18 from South China Sea. Mar. Drugs 2022, 20, 322. [Google Scholar] [CrossRef] [PubMed]
  13. Magot, F.; Van Soen, G.; Buedenbender, L.; Li, F.J.; Soltwedel, T.; Grauso, L.; Mangoni, A.; Blümel, M.; Tasdemir, D. Bioactivity and metabolome mining of deep-sea sediment-derived microorganisms reveal new hybrid PKS-NRPS macrolactone from Aspergillus versicolor PS108-62. Mar. Drugs 2023, 21, 95. [Google Scholar] [CrossRef]
  14. Lin, S.; Yu, H.M.; Yang, B.Y.; Li, F.L.; Chen, X.; Li, H.Q.; Zhang, S.T.; Wang, J.P.; Hu, Y.C.; Hu, Z.X.; et al. Reisolation and configurational reinvestigation of cottoquinazolines E–G from an arthropod-derived strain of the fungus Neosartorya fischeri. J. Nat. Prod. 2020, 83, 169–173. [Google Scholar] [CrossRef]
  15. Xu, W.F.; Mao, N.; Xue, X.J.; Qi, Y.X.; Wei, M.Y.; Wang, C.Y.; Shao, C.L. Structures and absolute configurations of diketopiperazine alkaloids chrysopiperazines A–C from the gorgonian-derived Penicillium chrysogenum fungus. Mar. Drugs 2019, 17, 250. [Google Scholar] [CrossRef]
  16. Hamasaki, T.; Nagayama, K.; Hatsuda, Y. Two new metabolites, sydonic acid and hydroxysydonic acid, from Aspergillus sydowi. Agric. Biol. Chem. 1978, 42, 37–40. [Google Scholar] [CrossRef]
  17. Lu, Z.Y.; Zhu, H.J.; Fu, P.; Wang, Y.; Zhang, Z.H.; Lin, H.P.; Liu, P.P.; Zhuang, Y.B.; Hong, K.; Zhu, W.M. Cytotoxic polyphenols from the marine-derived fungus Penicillium expansum. J. Nat. Prod. 2010, 73, 911–914. [Google Scholar] [CrossRef]
  18. Li, X.D.; Li, X.M.; Xu, G.M.; Zhang, P.; Wang, B.G. Antimicrobial phenolic bisabolanes and related derivatives from Penicillium aculeatum SD-321, a deep sea sediment-derived fungus. J. Nat. Prod. 2015, 78, 844–849. [Google Scholar] [CrossRef]
  19. Zheng, L.J.; Wang, H.W.; Fan, A.L.; Li, S.M. Oxepinamide F biosynthesis involves enzymatic D-aminoacyl epimerization, 3H-oxepin formation, and hydroxylation induced double bond migration. Nat. Commun. 2020, 11, 4914. [Google Scholar] [CrossRef]
  20. Sheldrick, G.M. SADABS, Software for Empirical Absorption Correction; University of Göttingen: Göttingen, Germany, 1996. [Google Scholar]
  21. Sheldrick, G.M. SHELXTL, Structure Determination Software Programs; Bruker Analytical X-ray System Inc.: Madison, WI, USA, 1997. [Google Scholar]
  22. Sheldrick, G.M. SHELXL-97 and SHELXS-97, Program for X-ray Crystal Structure Solution and Refinement; University of Göttingen: Göttingen, Germany, 1997. [Google Scholar]
  23. Parsons, S.; Flack, H.D.; Wagner, T. Use of intensity quotients and differences in absolute structure refinement. Acta Crystallogr. Sect. B Struct. Sci. Cryst. Eng. Mater. 2013, B69, 249–259. [Google Scholar] [CrossRef]
  24. Pierce, C.G.; Uppuluri, P.; Tristan, A.R.; Wormley, F.L.; Mowat, E.; Ramage, G.; Lopez-Ribot, J.L. A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing. Nat. Protoc. 2008, 3, 1494–1500. [Google Scholar] [CrossRef] [PubMed]
  25. Yan, L.H.; Li, P.H.; Li, X.M.; Yang, S.Q.; Liu, K.C.; Wang, B.G.; Li, X. Chevalinulins A and B, proangiogenic alkaloids with a spiro [bicyclo [2.2. 2] octane-diketopiperazine] skeleton from deep-sea cold-seep-derived fungus Aspergillus chevalieri CS-122. Org. Lett. 2022, 24, 2684–2688. [Google Scholar] [CrossRef] [PubMed]
Figure 1. Structures of compounds 112, versicomides A and B, and (−)-isoversicomide A.
Figure 1. Structures of compounds 112, versicomides A and B, and (−)-isoversicomide A.
Marinedrugs 21 00293 g001
Figure 2. Key COSY (bold lines) and HMBC (blue arrows) correlations for compounds 1, 2, and 4.
Figure 2. Key COSY (bold lines) and HMBC (blue arrows) correlations for compounds 1, 2, and 4.
Marinedrugs 21 00293 g002
Figure 3. Key NOE correlations for compounds 1, 2, and 4 (red lines: β-orientation; blue lines: α-orientation).
Figure 3. Key NOE correlations for compounds 1, 2, and 4 (red lines: β-orientation; blue lines: α-orientation).
Marinedrugs 21 00293 g003
Figure 4. X-ray crystal structures of compounds 1 and 3.
Figure 4. X-ray crystal structures of compounds 1 and 3.
Marinedrugs 21 00293 g004
Figure 5. Comparison of the experimental ECD spectra of compounds 3 (in red) and 4 (in blue) in CH3OH.
Figure 5. Comparison of the experimental ECD spectra of compounds 3 (in red) and 4 (in blue) in CH3OH.
Marinedrugs 21 00293 g005
Table 1. 1H (500 MHz) and 13C (125 MHz) NMR Spectroscopic Data for Compounds 1 and 2.
Table 1. 1H (500 MHz) and 13C (125 MHz) NMR Spectroscopic Data for Compounds 1 and 2.
Compound 1 aCompound 2 b
No.δC, TypeδH (Mult, J in Hz)HMBC
(From H to C)
δC, TypeδH (Mult, J in Hz)HMBC
(From H to C)
1168.0, C 167.1, C
2 8.40, br s1, 3, 4, 14 8.02, br s4
358.1, CH4.70, d (1.7)4, 15, 16, 18121.3, C
4149.3, C 144.3, C
6141.4, C 141.7, C
7129.5, CH7.61, d (8.9)9, 11129.3, CH7.62, d (8.9)9, 11
8124.9, CH7.45, dd (8.9, 2.9)6, 7, 10125.1, CH7.35, dd (8.9, 2.9)6
9158.5, C 159.0, C
10106.8, CH7.52, d (2.9)6, 8, 12106.4, CH7.65, d (2.9)6, 8
11120.9, C 120.8, C
12160.7, C 160.9, C
1460.9, CH4.93, d (8.7)1, 4, 12, 2061.2, CH5.33, dd (8.3, 1.5)1, 4, 20
1536.1, CH2.62, m 135.0, C
1623.5, CH21.34, m15, 1727.8, CH22.29, m3, 15
1712.9, CH30.86, overlap15, 1611.6, CH31.15, t (7.6)15, 16
1815.5, CH31.13, d (7.2)3, 15, 1619.5, CH32.35, s3, 15, 16
1956.2, CH33.88, s956.0, CH33.92, s9
2030.8, CH2.26, m 32.2, CH2.17, m
2120.2, CH30.86, overlap14, 20, 2219.8, CH31.01, d (6.8)14, 20, 22
2219.5, CH31.04, d (6.6)14, 20, 2119.0, CH31.09, d (6.8)14, 20, 21
a Recorded in DMSO-d6. b Recorded in CDCl3.
Table 2. 1H (500 MHz) and 13C (125 MHz) NMR data for compound 4 (in DMSO-d6).
Table 2. 1H (500 MHz) and 13C (125 MHz) NMR data for compound 4 (in DMSO-d6).
Compound 4
No.δC, TypeδH (Mult, J in Hz)HMBC
(From H to C)
1167.8, C
2 9.10, d, (5.1)4, 14
365.4, CH5.22, d, (5.1)1, 4, 18, 20
4147.4, C
6146.7, C
7127.2, CH7.74, dd, (8.4,1.0)9, 11
8134.4, CH7.84, ddd, (8.4, 7.1, 1.5)6, 10
9127.1, CH7.55, ddd, (8.1, 7.1, 1.0)7, 11
10126,1, CH8.13, dd, (8.0, 1.5)6, 8, 12
11120.7, C
12159.3, C
1453.8, CH5.27, dd, (5.3, 2.4)1, 15, 17
1536.3, CH23.08, dd, (14.9, 5.3)
2.42, dd, (14.9, 2.4)
17, 18
1, 14
1773.9, C
1879.6, CH4.87, d (1.8)3, 17
2068.1, CH4.06, m
21164.6, C
23135.9, C
24113.6, CH7.29, overlap26, 28
25129.3, CH7.29, overlap23, 27
26124.3, CH7.09, ddd (7.6, 4.2, 3.4)24, 25, 28
27124.4, CH7.42, d, (7.6)17, 25
28139.6, C-
2921.0, CH21.90, m
1.99, m
21, 30
308.9, CH31.06, t, (7.4)20, 29
17-OH 5.35, s15, 17, 18
Table 3. The antimicrobial activities of compounds 112 (MIC, μM) a.
Table 3. The antimicrobial activities of compounds 112 (MIC, μM) a.
Strains123456789101112Positive Control
A. hydrophila--18.6---------6.2 b
E. coli---72.2--------6.2 b
M. luteus--74.636.1--------3.1 b
V.harveyi--37.318.1---15.015.228.4--3.1 b
V. parahaemolyticus--37.39.0---15.0121.2113.5113.564.03.1 b
V. vulnificus--74.672.2--------3.1 b
C. spicifera93.3187.774.672.2-170.1------1.1 c
C. gloeosporioides186.6-74.672.289.1170.1164.5120.3121.2---2.2 c
a (-) = MIC > 200 μM; Positive control: b Chloromycetin; c amphotericin B.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Dong, Y.-L.; Li, X.-M.; Shi, X.-S.; Wang, Y.-R.; Wang, B.-G.; Meng, L.-H. Diketopiperazine Alkaloids and Bisabolene Sesquiterpenoids from Aspergillus versicolor AS-212, an Endozoic Fungus Associated with Deep-Sea Coral of Magellan Seamounts. Mar. Drugs 2023, 21, 293. https://doi.org/10.3390/md21050293

AMA Style

Dong Y-L, Li X-M, Shi X-S, Wang Y-R, Wang B-G, Meng L-H. Diketopiperazine Alkaloids and Bisabolene Sesquiterpenoids from Aspergillus versicolor AS-212, an Endozoic Fungus Associated with Deep-Sea Coral of Magellan Seamounts. Marine Drugs. 2023; 21(5):293. https://doi.org/10.3390/md21050293

Chicago/Turabian Style

Dong, Yu-Liang, Xiao-Ming Li, Xiao-Shan Shi, Yi-Ran Wang, Bin-Gui Wang, and Ling-Hong Meng. 2023. "Diketopiperazine Alkaloids and Bisabolene Sesquiterpenoids from Aspergillus versicolor AS-212, an Endozoic Fungus Associated with Deep-Sea Coral of Magellan Seamounts" Marine Drugs 21, no. 5: 293. https://doi.org/10.3390/md21050293

APA Style

Dong, Y. -L., Li, X. -M., Shi, X. -S., Wang, Y. -R., Wang, B. -G., & Meng, L. -H. (2023). Diketopiperazine Alkaloids and Bisabolene Sesquiterpenoids from Aspergillus versicolor AS-212, an Endozoic Fungus Associated with Deep-Sea Coral of Magellan Seamounts. Marine Drugs, 21(5), 293. https://doi.org/10.3390/md21050293

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop